J-HAQ score progression for each set of remission criteria over 2.5 years.
| N | Boolean Trial | SDAI | Boolean Practice | CDAI | DAS28 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All Cases | ΔJ-HAQ, Mean (SE) | J-HAQ Progression, % | All Cases | ΔJ-HAQ, Mean (SE) | J-HAQ Progression, % | All Cases | ΔJ-HAQ, Mean (SE) | J-HAQ Progression, % | All Cases | ΔJ-HAQ, Mean (SE) | J-HAQ Progression, % | All Cases | ΔJ-HAQ, Mean (SE) | J-HAQ Progression, % | |
| 0 | 222 | 0.11 (0.02) | 45.5 | 87 | 0.13 (0.04) | 47.1 | 212 | 0.10 (0.02) | 45.3 | 100 | 0.12 (0.04) | 47.0 | — | — | — |
| 1 | 130 | 0.05 (0.02) | 30.8 | 97 | 0.10 (0.03) | 47.4 | 123 | 0.06 (0.02) | 31.7 | 102 | 0.12 (0.02) | 47.1 | 63 | 0.16 (0.04) | 57.1 |
| 2 | 112 | 0.05 (0.04) | 29.5 | 112 | 0.06 (0.03) | 33.9 | 111 | 0.04 (0.04) | 28.8 | 107 | 0.02 (0.03) | 29.0 | 70 | 0.18 (0.05) | 40.0 |
| 3 | 102 | 0.06 (0.02) | 27.5 | 118 | 0.04 (0.02) | 25.4 | 99 | 0.05 (0.02) | 27.3 | 134 | 0.04 (0.02) | 27.6 | 128 | 0.07 (0.03) | 36.7 |
| 4 | 102 | 0.01 (0.02) | 19.6 | 125 | 0.10 (0.03) | 32.0 | 100 | 0.04 (0.03) | 24.0 | 117 | 0.10 (0.03) | 31.6 | 161 | 0.08 (0.02) | 34.2 |
| 5 | 86 | 0.03 (0.02) | 17.4 | 129 | 0.01 (0.02) | 24.0 | 95 | 0.03 (0.02) | 20.0 | 128 | 0.02 (0.02) | 24.2 | 175 | 0.00 (0.02) | 20.6 |
| 6 | 161 | −0.02 (0.01) | 6.2 | 247 | −0.01 (0.01) | 8.5 | 175 | −0.01 (0.01) | 5.7 | 227 | −0.01 (0.01) | 7.1 | 318 | −0.01 (0.01) | 14.2 |
N: no. data collections in which patients fulfilled remission criteria; ΔJ-HAQ: the value resulting from the subtraction of October 2010 J-HAQ scores from April 2008 J-HAQ scores; J-HAQ: Japanese version of the Health Assessment Questionnaire; SDAI: Simplified Disease Activity Index; CDAI: Clinical Disease Activity Index; DAS28: 28-joint Disease Activity Score; SE: standard error.